デフォルト表紙
市場調査レポート
商品コード
1225145

子宮内膜症市場:タイプ別、治療別(経口避妊薬、ゴナドトロピン放出ホルモン薬、その他)、流通チャネル別:世界の機会分析と産業予測、2021-2031年

Endometriosis Market By Type, By Treatment (Oral contraceptives, Gonadotropin-releasing hormone medicines, Others), By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
子宮内膜症市場:タイプ別、治療別(経口避妊薬、ゴナドトロピン放出ホルモン薬、その他)、流通チャネル別:世界の機会分析と産業予測、2021-2031年
出版日: 2022年12月01日
発行: Allied Market Research
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

子宮内膜症市場は、2021年に12億3,981万米ドルと評価され、2022年から2031年にかけて12.6%のCAGRを記録し、2031年には39億2,641万米ドルに到達すると予測されています。

子宮内膜症は、子宮内膜組織が子宮の外で増殖する病気の一種です。子宮内膜症は、子宮内膜に似た組織が卵巣、卵管、その他の骨盤内構造物など子宮腔以外に存在する疾患と定義されています。子宮内膜症は4つのタイプに分けられます。表在性腹膜子宮内膜症、子宮内膜腫、深在性子宮内膜症、腹壁内膜症などです。子宮内膜症は、生理痛、大量出血、排尿痛、頻便、便秘、性交時の激痛、慢性骨盤痛、腹部膨満感などを引き起こすことがあります。子宮内膜症は不妊症の原因となり、卵巣がんのリスクを高める可能性があります。

現在、子宮内膜症を治療する方法はありませんが、子宮内膜症に伴う疼痛は薬物療法で管理することが可能です。ルプロン・デポ(リュープロリド)、シナレル(ナファレリン)、ゾラデックス(ゴセレリン)などのゴナドトロピン放出ホルモン(GnRH)薬やプロベラ(メドロキシプロゲステロン)、スプリンテック(エチニルエストラジオール)などの経口避妊薬が、内膜症の管理には使用されています。

子宮内膜症市場の成長を促進する主な要因としては、新薬やホルモン療法に対する需要の増加、世界人口の早期診断と子宮内膜症の治療に関する意識の高まり、生検や超音波などの高度な診断方法の利用可能性の増加、子宮内膜症の有病率の上昇などが挙げられます。例えば、世界保健機関(WHO)の2021年報告によると、約1億9000万人の生殖年齢の女性が子宮内膜症であり、世界の女性人口の約10%を占めています。

さらに、ドラッグデリバリー技術の進歩、子宮内膜症の管理に薬剤の組み合わせを使用することに関する研究の増加により、ヘルスケア事業が成長を示すと予測され、子宮内膜症市場の成長を促進します。例えば、2022年1月、製薬技術によると、2つのGnRH拮抗薬、ObsEvaのYselty(リンザゴリックス)とMyovant Sciences/PfizerのRelugolixコンビネーションタブレットが、今後2年間で米国、欧州5大都市(フランス、ドイツ、イタリア、スペイン、英国)および日本の7大製薬市場全体で発売予定であるとのことです。レルゴリックスは、まず日本で発売し、2022年に同市場に参入する予定です。これらの薬剤は、欧州の5大市場と日本で初めて発売されるGnRH拮抗薬であり、子宮内膜症市場を大幅に強化することになります。

しかし、薬価の高さと診断率の低さが、子宮内膜症市場の成長を妨げると予想されます。一方、新興経済諸国における満たされない医療需要と新興諸国における有利なビジネスチャンスは、将来的に世界中の子宮内膜症治療薬メーカーに計り知れない機会をもたらすと予想されます。

さらに、急速に進歩する世界のヘルスケアインフラ、女性の生殖に関する健康意識の高まり、インドや中国などの新興諸国における女性の健康に対する意識を高めるための政府の取り組みが、子宮内膜症市場の成長を後押ししています。このため、予測期間中、主要企業が同市場へ投資するための有益な機会を提供すると予想されます。また、効果的な医薬品の発見・開発のための研究開発投資の増加、子宮内膜症の治療に関する研究に対する政府からの資金提供の増加、先進国における資本所得の大幅な増加が、市場の成長を促進します。例えば、2022年3月、米国連邦政府は、国立小児保健・人間開発研究所(NICHD)に9,200万米ドルの資金提供を発表し、子宮内膜症研究のために国防総省の査読付き医学研究プログラム(PRMRP)に3億7,000万米ドルを提供し続けています。

さらに、主要なプレーヤーが採用する製品発売、パートナーシップ、製品承認、コラボレーション、合併、買収などの主要戦略の上昇は、市場における子宮内膜症の管理のための薬物の需要を強化します。例えば、2022年8月、Myovant Sciences社とPfizer Inc.は、米国食品医薬品局(FDA)が、中等度から重度の子宮内膜症に伴う痛みの1日1回の治療薬としてMyfembree(relugolix 40 mg、estradiol 1 mg、norethindrone acetate 0.5 mg)を承認したと発表しました。今回の承認は、アンメットニーズが高い分野における女性の健康に対するファイザーとMyovant社のコミットメントを反映する重要なマイルストーンとなります。したがって、このような要因が子宮内膜症市場の成長を後押ししています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資ポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 適度な競争の激しさ
  • 市場力学
    • 促進要因
      • 子宮内膜症の調査に対する資金の増加
      • 子宮内膜症に関する意識の高まり
    • 抑制要因
      • 子宮内膜症の治療費が高い
    • 機会
      • 研究開発活動の増加と最近の製品承認
  • 市場におけるCOVID-19影響分析

第4章 子宮内膜症市場:タイプ別

  • 概要
    • 市場規模と予測
  • 表在性腹膜病変
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • 子宮内膜腫
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別

第5章 子宮内膜症市場:治療別

  • 概要
    • 市場規模と予測
  • 経口避妊薬
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • ゴナドトロピン放出ホルモン(GnRH)薬
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別

第6章 子宮内膜症市場:流通チャネル別

  • 概要
    • 市場規模と予測
  • 病院薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • オンライン薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別
  • 小売薬局
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測:地域別
    • 市場シェア分析: 国別

第7章 子宮内膜症市場:地域別

  • 概要
    • 市場規模と予測:地域別
  • 北米
    • 主な動向と機会
    • 市場規模と予測:タイプ別
    • 市場規模と予測:治療別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • 米国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • カナダ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • メキシコ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
  • 欧州
    • 主な動向と機会
    • 市場規模と予測:タイプ別
    • 市場規模と予測:治療別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • ドイツ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • フランス
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • 英国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • イタリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • スペイン
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • その他欧州
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
  • アジア太平洋
    • 主な動向と機会
    • 市場規模と予測:タイプ別
    • 市場規模と予測:治療別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • 中国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • 日本
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • インド
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • オーストラリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • 韓国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主な動向と機会
    • 市場規模と予測:タイプ別
    • 市場規模と予測:治療別
    • 市場規模と予測:流通チャネル別
    • 市場規模と予測:国別
      • ブラジル
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • サウジアラビア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • 南アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別
      • ラテンアメリカ・中東・アフリカの残り
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測:タイプ別
      • 市場規模と予測:治療別
      • 市場規模と予測:流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • トップ 10プレーヤーの製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トッププレーヤーのポジショニング、2021

第9章 企業プロファイル

  • Abbott Laboratories
  • Consilient Health Limited
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Ltd
  • Abbvie Inc
  • AstraZeneca plc
図表

LIST OF TABLES

  • TABLE 01. GLOBAL ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. ENDOMETRIOSIS MARKET FOR SUPERFICIAL PERITONEAL LESION, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. ENDOMETRIOSIS MARKET FOR ENDOMETRIOMAS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. ENDOMETRIOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. ENDOMETRIOSIS MARKET FOR ORAL CONTRACEPTIVES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. ENDOMETRIOSIS MARKET FOR GONADOTROPIN-RELEASING HORMONE (GNRH) MEDICINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. ENDOMETRIOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. ENDOMETRIOSIS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. ENDOMETRIOSIS MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. ENDOMETRIOSIS MARKET FOR RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. ENDOMETRIOSIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. CHINA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CHINA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CHINA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. JAPAN ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. JAPAN ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. AUSTRALIA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA ENDOMETRIOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA ENDOMETRIOSIS MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA ENDOMETRIOSIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 88. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 89. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 90. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 91. CONSILIENT HEALTH LIMITED: KEY EXECUTIVES
  • TABLE 92. CONSILIENT HEALTH LIMITED: COMPANY SNAPSHOT
  • TABLE 93. CONSILIENT HEALTH LIMITED: PRODUCT SEGMENTS
  • TABLE 94. CONSILIENT HEALTH LIMITED: PRODUCT PORTFOLIO
  • TABLE 95. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 96. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 97. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 98. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 99. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES
  • TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT
  • TABLE 102. MERCK & CO. INC.: PRODUCT SEGMENTS
  • TABLE 103. MERCK & CO. INC.: PRODUCT PORTFOLIO
  • TABLE 104. PFIZER INC.: KEY EXECUTIVES
  • TABLE 105. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 106. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 107. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 108. SANOFI: KEY EXECUTIVES
  • TABLE 109. SANOFI: COMPANY SNAPSHOT
  • TABLE 110. SANOFI: PRODUCT SEGMENTS
  • TABLE 111. SANOFI: PRODUCT PORTFOLIO
  • TABLE 112. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 113. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 114. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 115. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: SERVICE SEGMENTS
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 124. TORRENT PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 125. TORRENT PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 126. TORRENT PHARMACEUTICALS LTD: PRODUCT SEGMENTS
  • TABLE 127. TORRENT PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 128. ABBVIE INC: KEY EXECUTIVES
  • TABLE 129. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 130. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 131. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 132. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 133. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 134. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 135. ASTRAZENECA PLC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ENDOMETRIOSIS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF ENDOMETRIOSIS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN ENDOMETRIOSIS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALENDOMETRIOSIS MARKET
  • FIGURE 10. ENDOMETRIOSIS MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR SUPERFICIAL PERITONEAL LESION, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR ENDOMETRIOMAS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. ENDOMETRIOSIS MARKET, BY TREATMENT, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR ORAL CONTRACEPTIVES, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR GONADOTROPIN-RELEASING HORMONE (GNRH) MEDICINES, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR ONLINE PHARMACY, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ENDOMETRIOSIS MARKET FOR RETAIL PHARMACY, BY COUNTRY 2021-2031(%)
  • FIGURE 22. ENDOMETRIOSIS MARKET BY REGION, 2021
  • FIGURE 23. U.S. ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. CHINA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA ENDOMETRIOSIS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: ENDOMETRIOSIS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 50. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. MERCK & CO. INC.: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 56. MERCK & CO. INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. MERCK & CO. INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. SANOFI: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. SANOFI: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021
  • FIGURE 63. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 64. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 65. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. TORRENT PHARMACEUTICALS LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 70. TORRENT PHARMACEUTICALS LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 73. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 74. ASTRAZENECA PLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 75. ASTRAZENECA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 76. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A47225

The endometriosis market was valued at valued at $1,239.81 million in 2021, and is projected to reach $3,926.41 million by 2031, registering a CAGR of 12.6% from 2022 to 2031.

Endometriosis is a type of disease in which endometrial tissue grows outside the uterus. Endometriosis is defined as a condition where tissue similar to the lining of the uterus is found outside of the uterine cavity such as on the ovaries, fallopian tubes, or other pelvic structures. Endometriosis are of four types. These include superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Endometriosis can lead to pain during periods, excessive bleeding, painful urination, frequent bowel movements, constipation, severe pain during sexual intercourse, chronic pelvic pain, and abdominal bloating. Endometriosis can cause infertility and increase the risk of ovarian cancer.

There is currently no cure for endometriosis, however pain associated with endometriosis can be managed with medication. The gonadotropin-releasing hormone (GnRH) medicines such as Lupron Depot (leuprolide), Synarel (nafarelin), Zoladex (goserelin) and oral contraceptive such as Provera (medroxyprogesterone), Sprintec (ethinyl estradiol) are used for the management of endometriosis.

Major factors driving growth of the endometriosis market include rise in demand for novel drugs and hormonal therapies, rise in awareness regarding early disease diagnosis and treatment of endometriosis among global population and increasing availability of advanced diagnostic methods such as biopsy, ultrasound and rise in the prevalence of endometriosis. For instance, according to the world health organization (WHO) 2021 report, about 190 million reproductive-age females have endometriosis, accounting for about 10% of the female population globally.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in advancement in drug delivery technologies, rise in research regarding using combination of drug for the management of endometriosis drives the growth of endometriosis market. For instance, in January 2022, according to pharmaceutical technology, two GnRH antagonists, ObsEva's Yselty (linzagolix) and Myovant Sciences/Pfizer's Relugolix combination tablet, are set to launch across the seven major pharmaceutical markets, the US, five major European markets (France, Germany, Italy, Spain, and the UK) and Japan, in the next two years. Relugolix will launch in Japan first, entering that market in 2022. These medications will be the first GnRH antagonists launched in the five major European markets and Japan, which will bolster the endometriosis market significantly.

However, the high cost of medicine and low diagnostic rate is expected to hamper the growth of the endometriosis market. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for endometriosis medicine manufacturers worldwide in the future.

Moreover, rapidly advancing global healthcare infrastructure, rise in awareness regarding female reproductive health, increasing government initiatives to raise awareness about women's health in developing countries like India, China drives the growth of endometriosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period. In addition, a rise in R&D investments in discovery & development of effective medicine, rise in funding from government for research regarding treatment of endometriosis and significant rise in capital income in developed countries drives the growth of the market. For instance, in March 2022, the U.S. federal government announced $92 million funds to National Institute of Child Health and Human Development (NICHD) and continues to provide $370 million to the Department of Defense's Peer-Reviewed Medical Research Program (PRMRP) for endometriosis research.

Furthermore, the rise in key strategies include product launch, partnership, product approval, collaboration, merger, acquisition adopted by key players strengthen demand of medication for the management of endometriosis in the market. For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant's commitment to women's health in areas of significant unmet need. Hence, such factors drive the growth of the endometriosis market.

The endometriosis market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is classified into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). On the basis of treatment, the market is classified into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. Depending on the distribution channel, it is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Consilient Health Limited, GlaxoSmithKline plc, Merck & Co. Inc, Pfizer Inc, Sanofi India Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the endometriosis market analysis from 2021 to 2031 to identify the prevailing endometriosis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the endometriosis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global endometriosis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Superficial peritoneal lesion
  • Endometriomas
  • Others

By Distribution channel

  • Hospital pharmacy
  • Online pharmacy
  • Retail pharmacy

By Treatment

  • Oral contraceptives
  • Gonadotropin-releasing hormone (GnRH) medicines
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Consilient Health Limited
    • Serum Institute of India Pvt. Ltd.
    • Abbott Laboratories
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • AstraZeneca plc
    • Abbvie Inc
    • Sanofi
    • Sun Pharmaceutical Industries Ltd
    • Torrent Pharmaceuticals Ltd
    • Teva Pharmaceutical Industries Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in funding for research of endometriosis
      • 3.4.1.2. Rise in awareness regarding endometriosis
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of endometriosis medicine
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in R&D activities and recent product approval
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ENDOMETRIOSIS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Superficial peritoneal lesion
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Endometriomas
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: ENDOMETRIOSIS MARKET, BY TREATMENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral contraceptives
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Gonadotropin-releasing hormone (GnRH) medicines
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online pharmacy
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Retail pharmacy
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ENDOMETRIOSIS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Treatment
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Treatment
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Treatment
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Treatment
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Treatment
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Treatment
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Treatment
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Treatment
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Treatment
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Treatment
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Treatment
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Treatment
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Treatment
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Treatment
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Treatment
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Treatment
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Treatment
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Treatment
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Treatment
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Treatment
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Treatment
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Treatment
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Treatment
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Consilient Health Limited
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. GlaxoSmithKline plc
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Merck & Co. Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Pfizer Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Sanofi
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Serum Institute of India Pvt. Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. Sun Pharmaceutical Industries Ltd
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Torrent Pharmaceuticals Ltd
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
  • 9.11. Abbvie Inc
    • 9.11.1. Company overview
    • 9.11.2. Key Executives
    • 9.11.3. Company snapshot
    • 9.11.4. Operating business segments
    • 9.11.5. Product portfolio
    • 9.11.6. Business performance
  • 9.12. AstraZeneca plc
    • 9.12.1. Company overview
    • 9.12.2. Key Executives
    • 9.12.3. Company snapshot
    • 9.12.4. Operating business segments
    • 9.12.5. Product portfolio
    • 9.12.6. Business performance